Stenting And Thrombectomy Systems Fuel Neuro Device Market Growth
Executive Summary
Advances in distally protected carotid artery stenting systems and second-generation cerebral thrombectomy devices will help drive strong growth in the US neurointerventional device market over the next five years. The market, which includes endovascular devices for the treatment of cerebral aneurysms, arteriovenous malformations, stroke, and carotid artery disease, is projected to grow at a compound annual rate of 6.5%, and reach more than $846 million by 2018.
You may also be interested in...
ASH 2020: J&J/Legend’s Cilta-Cel Shines, But BMS/Bluebird’s Ide-Cel Is In First Place
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
The Race To Develop A COVID-19 Vaccine: mRNA Pioneers Lead The Way
Our updated graphic tracker of key developments from the leading vaccine candidates.
LOXO-305 Comes Out Swinging In Battle Of BTK Inhibitors
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: